VKTX
Viking Therapeutics, Inc.
Key Financials
Operating Income
$-393342000
↓ 160.6%
Net Income
$-359639000
↓ 227.1%
Revenue
$0
NaN%
Total Assets
$715.7M
↓ 21.2%
Shareholders' Equity
$639.1M
↓ 27.4%
Total Liabilities
$76.7M
↑ 173.4%
Cash & Equivalents
$165.8M
↑ 521.6%
EPS (Diluted)
$-3.19
↓ 215.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| ARS | 4/1/2026 | View on SEC |
| DEFA14A | 4/1/2026 | View on SEC |
| DEF 14A | 4/1/2026 | View on SEC |
| SCHEDULE 13G/A | 3/27/2026 | View on SEC |
| 4 | 3/10/2026 | View on SEC |
| 10-K | 2/11/2026 | View on SEC |
| 8-K | 2/11/2026 | View on SEC |
| 4 | 1/26/2026 | View on SEC |
| 3 | 1/26/2026 | View on SEC |
| 4 | 1/5/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | VKTX |
| Company Name | Viking Therapeutics, Inc. |
| CIK | 1607678 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 858-704-4660 |